About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGNA

Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)

Esophageal Stent With or Without Anti-migration Device for Tumors of the Gastroesophageal Junction: Multicenter Randomized Controlled Study. ANTIMIG Study

NCT05431738•Société Française d'Endoscopie Digestive

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Stent MigrationGastroEsophageal Cancer

Interventions

Gastroesophageal stent placement

Locations

1

France

Locations (1)

French Society of Digestive Endoscopy

Paris, France

Key Dates

Start Date

September 1, 2022

Primary Completion Date

September 1, 2025

Completion Date

September 1, 2025

Last Updated

July 30, 2024

Related Studies

RECRUITINGPhase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264

Breast CancerSmall Cell Lung Cancer+10 more

RECRUITINGPhase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871

HER2 Mutation-Related TumorsHER2+11 more

Active Not RecruitingPhase 1/2

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

NCT03610711

Gastroesophageal CancerImmune Checkpoint Inhibition

Active Not RecruitingNA

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients

NCT05438940

GastroEsophageal Cancer

Active Not RecruitingPhase 1/2

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

NCT05632939

Gastric CancerGastroesophageal Cancer (GC)

Active Not RecruitingPhase 2

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

NCT04164979

Gastric AdenocarcinomaGastroEsophageal Cancer

View all related studies

Contacts

David KARSENTI, MD

CONTACT

+33603454293 karsenti@club-internet.fr

Sponsors

Lead Sponsor

Société Française d'Endoscopie Digestive

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2024Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions